Pharmacopoeia Of The | People 39-s Republic Of China Pdf
The National Pharmacopoeia Commission publishes an official English version of each edition, which is vital for non-Chinese regulatory teams managing global QA/QC workflows. Compliance and Quality Control Implications
The Pharmacopoeia of the People's Republic of China is a comprehensive document that covers a wide range of medicinal products, including traditional Chinese medicines, Western medicines, and biological products. The pharmacopoeia is divided into several sections, including:
First published in 1953, the Chinese Pharmacopoeia has evolved to mirror China's massive strides in biotechnology and raw material production. Operating on a strict five-year update cycle, every new edition represents an expansion of drug safety parameters and a stricter push toward international alignment. pharmacopoeia of the people 39-s republic of china pdf
Manufacturers exporting pharmaceuticals to China must audit their internal testing procedures against the current ChP methods. If the ChP specifies a testing method or impurity limit that differs from the USP or Ph. Eur., the manufacturer must validate and perform the ChP-specified test to clear China's customs and National Institutes for Food and Drug Control (NIFDC) testing.
The National Pharmacopoeia Commission of China updates the ChP every five years to reflect advancements in analytical chemistry, biological testing, and manufacturing technologies. Operating on a strict five-year update cycle, every
Ensuring production processes comply with current standards (e.g., specific testing methods in Volume IV).
The official publisher is the .
The Chinese Pharmacopoeia places significant emphasis on traditional Chinese medicine (TCM), which is an integral part of China's healthcare system. TCM has a long history dating back thousands of years, and its practices and products have gained popularity worldwide. The pharmacopoeia includes monographs on TCM products, such as: